
    
      Patients who consent to participate in this study will receive treatment with rucaparib and
      bevacizumab until unacceptable toxicity or tumor progression. Subjects will take one
      rucaparib pill will be taken twice daily, and bevacizumab will be adimistered via IV onDay 1
      of each 21 day cycle. Subjects will receive tests and procedures that are part of regular
      cancer care as well as those required for the purposes of this study. If there is no cancer
      found in scans after 6 cycles of treatment, patients may continue with study treatment for 1
      year. Follow up visits will occur every 3 months for the first 2 years after treatment is
      completed and every 6 months for 3 additional years.
    
  